The first three years of buprenorphine in the United States: experience to date and future directions.
about
Update on the clinical use of buprenorphine: in opioid-related disordersUtilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependenceImproving temporal efficiency of outpatient buprenorphine induction.Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trialAwareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program.Consumer attitudes about opioid addiction treatment: a focus group study in New York City.A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network.Factors affecting willingness to provide buprenorphine treatment.The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment.Estimating the prevalence of illicit opioid use in New York City using multiple data sources.Integrating buprenorphine treatment into office-based practice: a qualitative studyBuprenorphine implant for opioid addictionA comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions.Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.Supply of buprenorphine waivered physicians: the influence of state policies.Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel ProcessCost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural CountiesBuprenorphine Prescribing Availability in a Sample of Ohio Specialty Treatment OrganizationsA randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African AmericansFactors associated with complicated buprenorphine inductionsA contingency-management intervention to promote initial smoking cessation among opioid-maintained patients.Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphinePerceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxification.Narrative review: buprenorphine for opioid-dependent patients in office practice.Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes.Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients.A buprenorphine education and training program for primary care residents: implementation and evaluation.Training physicians to treat substance use disordersInquiries about and initiation of buprenorphine treatment in an inner-city clinicI heard about it from a friend: assessing interest in buprenorphine treatment.Looking for the uninsured in Massachusetts? Check opioid dependent persons seeking detoxification.The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here.Mise à jour sur l’utilisation clinique de la buprénorphine: pour les troubles reliés aux opioïdes.At the Expense of a Life: Race, Class, and the Meaning of Buprenorphine in Pharmaceuticalized "Care".
P2860
Q26829140-6A7CC579-BD2D-4365-8A8B-716993CDBA2EQ26865674-0F9E454B-AC90-4E91-9B0C-0199C8918824Q30425074-A698E780-D850-4B5E-A3CC-07E2A36020F8Q30432435-B4D8EC78-9205-492A-90D8-AD3176129828Q33576948-66132933-52B5-4B11-B1C3-61C419B5FCD8Q33576957-CA44895C-AF1E-4B86-B6C9-792545962964Q33750845-A7AAD833-C0AE-4D77-8D34-78EDBEE71098Q33836333-E038B27A-8DA9-4352-8B15-BE45C9EEBDA8Q34050760-FF0836FF-5B3E-41EA-80D2-7427BC29C7C2Q34309396-C757E9BC-E98E-40DA-BE58-E7B86D78B445Q34602077-0A1EDC4E-9A2B-40ED-81EC-FBED4DF02611Q34820000-53E8C990-EF34-45DE-8C0D-EA304BECA73AQ34850334-EA4E77C0-D33D-4AFF-B7A9-17565C48F97DQ35400440-9A8C42C0-C0B4-42AB-A817-B75C6C963EF6Q35491054-481477DC-F15A-44F0-9D93-933416B90C3AQ35540686-FF26A41B-998A-4161-AD7D-F908CFC79E22Q35571613-96B23FEE-895E-4096-895C-594308664D61Q35752218-16688693-68C0-478A-9424-D4878B22E6BDQ35980664-1E9D9FF2-D60F-4EBA-AA13-D45831C4D459Q36054084-0A2E1297-2B93-4CFD-BC79-525C42C2F76BQ36058075-7C7C4312-4746-43F6-9AF3-50F478BDF2BDQ36579283-72D588CB-D2EA-45B6-9A69-576A0E3CB89AQ36585261-49690CD6-B0CE-4E40-B0A3-86818EC79065Q36708879-6D49943C-A432-4271-B490-37AA9FF46272Q36821137-F5B509F4-017E-4CF9-A156-AB36CF21B62AQ36920487-CF6C9AF7-ADFC-443D-97E2-082DF749AC29Q36959052-6317B539-EDC1-4762-ABE6-AC5EDE362FD8Q36960916-8E582D3D-F8BB-4C68-945D-43B12FEE48FFQ37079839-573C184A-D900-482B-BDD1-31259AE96BC4Q37105100-BB14534A-2F55-4B32-84FE-090CED92BDB6Q37237877-7265EFA6-1D18-4765-B6CB-38412E9958A1Q37273938-090E9AC7-40B2-4481-B520-E3F183949009Q37353120-5D22C87B-0AFA-48CE-B18B-863DEB89BA76Q37617894-C71EC6E9-7E66-4F58-92A3-96FDD02ACBDCQ37631251-31767C4B-784E-49D4-B39D-546BFB15DEC6Q37729027-72569192-7699-4532-AB4D-ECD67EDAB1F6Q38786260-18416F85-E95B-41E1-B497-9EC653606A71Q45847009-54B44497-DC3E-4786-AE41-332F8F16568EQ47182845-528167D4-A91E-44C7-AE8B-B060F332CBF2
P2860
The first three years of buprenorphine in the United States: experience to date and future directions.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The first three years of bupre ...... to date and future directions.
@en
type
label
The first three years of bupre ...... to date and future directions.
@en
prefLabel
The first three years of bupre ...... to date and future directions.
@en
P1476
The first three years of bupre ...... to date and future directions.
@en
P356
10.1097/ADM.0B013E3180473C11
P577
2007-06-01T00:00:00Z